Fauna Bio Signs a Strategic Collaboration Agreement with Eli Lilly to Discover Obesity Targets through Convergence AI Platform
Shots:
- Fauna has entered into a multi-year agreement with Eli Lilly to discover multiple drug targets for obesity. The collaboration will leverage Fauna’s Convergence AI platform to identify novel targets for complex disease areas of high unmet need
- Under the terms of the agreement, Fauna will receive an up front payment including equity investments (both undisclosed) & is eligible to receive an aggregate of $494M in pre-clinical, clinical & commercial milestone payments plus royalties
- The Convergence AI platform utilizes genomic analyses across 452 mammal species incl. 65 hibernators and thereby identifies drug targets for humans by analyzing the data collected from the protective adaptations of hibernation biology
Ref: PR Newswire | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
